AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results.

Peritoneal Cancer ◽

Phase Iii Study ◽

Pazopanib Versus Placebo in Women Without Progression After First-Line Chemotherapy for Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Aeoc): Second Interim Overall Survival Analysis from the Ago-Ovar16 Trial

Annals of Oncology ◽

10.1093/annonc/mdu338.6 ◽

2014 ◽

Vol 25 ◽

pp. iv307

Author(s):

H. Nomura ◽

L. Hanker ◽

M. Fabbro ◽

J. Rau ◽

Y. Kim ◽

...

Keyword(s):

Overall Survival ◽

Survival Analysis ◽

Fallopian Tube ◽

First Line ◽

Peritoneal Cancer ◽

Overall Survival Analysis ◽

Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4016 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4016-4016 ◽

Cited By ~ 3

Author(s):

Yoon-Koo Kang ◽

Min-Hee Ryu ◽

Se Hoon Park ◽

Sook Ryun Park ◽

Jong Gwang Kim ◽

...

Keyword(s):

Gastric Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

First Line ◽

Phase Iii Study ◽

Line Chemotherapy ◽

Oral Paclitaxel

8033 Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71555-1 ◽

2009 ◽

Vol 7 (2) ◽

pp. 459

Author(s):

S. Nishio ◽

N. Katsumata ◽

K. Matsumoto ◽

H. Tanabe ◽

K. Yonemori ◽

...

Keyword(s):

Fallopian Tube ◽

First Line ◽

Peritoneal Cancer ◽

First Line Therapy ◽

Line Therapy ◽

Third Line ◽

Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdy055 ◽

2018 ◽

Vol 29 (5) ◽

pp. 1220-1226 ◽

Cited By ~ 10

Author(s):

Y.-K. Kang ◽

M.-H. Ryu ◽

S.H. Park ◽

J.G. Kim ◽

J.W. Kim ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

First Line ◽

Phase Iii Study ◽

Line Chemotherapy ◽

Oral Paclitaxel

A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps4138 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS4138-TPS4138

Author(s):

Sang Cheul Oh ◽

Min-Hee Ryu ◽

Se Hoon Park ◽

Baek-Yeol Ryoo ◽

Sook Ryun Park ◽

...

Keyword(s):

Gastric Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

First Line ◽

Recurrent Gastric Cancer ◽

Phase Iii Study ◽

Line Chemotherapy ◽

Oral Paclitaxel

6600 POSTER A Randomized, Multicenter, Open-label, Phase III Study to Compare the Efficacy and Safety of Capecitabine Plus Paclitaxel Followed by Capecitabine Maintenance (PX-X) With Capecitabine Plus Cisplatin (XP) as a First-line Chemotherapy for Recurrent or Metastatic Gastric Cancer (PAC-C Study)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71911-6 ◽

2011 ◽

Vol 47 ◽

pp. S471-S472

Author(s):

X. Zhang ◽

L. Shen ◽

Z. Lu ◽

B. Hu ◽

Q. Fan ◽

...

Keyword(s):

Gastric Cancer ◽

Metastatic Gastric Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-008-0488-x ◽

2008 ◽

Vol 135 (4) ◽

pp. 551-557 ◽

Cited By ~ 12

Author(s):

Shin Nishio ◽

Noriyuki Katsumata ◽

Koji Matsumoto ◽

Hiroshi Tanabe ◽

Kan Yonemori ◽

...

Keyword(s):

Fallopian Tube ◽

First Line ◽

Peritoneal Cancer ◽

First Line Therapy ◽

Line Therapy ◽

Third Line ◽

Faculty Opinions recommendation of Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958666.793464700 ◽

2012 ◽

Author(s):

Sandro Pignata ◽

Sabrina Cecere

Keyword(s):

Fallopian Tube ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Phase Iii ◽

Open Label ◽

Peritoneal Cancer ◽

Open Label Phase ◽

Phase Iii Study ◽

Platinum Refractory

1374P A randomized phase III study to compare efficacy and safety between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer (KCSG ST13-10)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1483 ◽

2021 ◽

Vol 32 ◽

pp. S1041

Author(s):

I. Choi ◽

K-W. Lee ◽

D.Y. Zang ◽

M.H. Ryu ◽

H.S. Han ◽

...

Keyword(s):

Gastric Cancer ◽

Combination Therapy ◽

Elderly Patients ◽

Advanced Gastric Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

First Line ◽

Phase Iii Study ◽

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Stage Iiib ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

First Line Treatment